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 ABSTRACT 
 
Drug discovery from marine organisms is gaining momentum and research focusing on 
marine actinomycete diversity has yielded numerous novel secondary metabolites with 
unique chemical structures.  
 
This study was based on targeted analyses of marine actinobacteria selected from a 
library of ca. 10.000 isolates cultivated from sediment- and sponge-samples in the 
Trondheim fjord, Norway. The two small sub-collections used in this study consisted of 
35 shallow-water sediment-derived actinomycetes (“sub-library I”) and 27 deep-water 
sediment- and sponge-derived actinobacterial isolates (“sub-library II”). The isolates in 
these collections were analyzed for: (i) the influence of seawater on growth; (ii) their 
phylogenetic diversity based on molecular taxonomy, and (iii) their antibiotic 
production potential.  
 
The presence of seawater had different effects on the growth of the studied isolates. A 
preference for seawater or an obligatory requirement indicated the presence of 
indigenous marine actinomycetes in sub-library I and was used as a criterion for 
selection of isolates in sub-library II. The preliminary classification of isolates was 
performed by 16S rRNA gene sequence analysis which revealed significant 
biodiversity. Representatives of 11 different actinomycete genera were identified in sub-
library I and members of 8 genera confirmed in sub-library II. The results of a PCR 
screening for polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) 
genes demonstrated the genetic potential to produce secondary metabolites with 
polyketide and/or non-ribosomal peptide backbones for the majority of isolates in both 
sub-libraries.  
 
Whole-cell based antimicrobial assays involving microtitre cultivations and multiple 
fermentation media were performed using isolates of sub-library II with the objective to 
find producers of new antibacterial or antifungal compounds. Extracts with antibacterial 
or antifungal activity were identified for more than 50% of the isolates subjected to this 
I 
 screening. Nine isolates produced compounds with activity against multi-resistant 
bacterial and/or fungal strains.  
 
Fermentation extracts of isolate Nocardiopsis sp. TFS65-07 from sub-library II 
displayed high activity against vancomycin-resistant Enterococcus faecium. The active 
antibacterial compound was purified from fermentation extracts of TFS65-07 and 
structure elucidation identified it as a new member of the thiopeptide antibiotic family. 
The gene cluster for biosynthesis of the new thiopeptide, TP-1161, was identified by 
mining a draft genome sequence obtained for the producing organism. The proposed 
identity of the cluster was confirmed by gene inactivation experiments. Bioinformatics 
analyses of genes constituting the cluster and their products allowed proposition of the 
biosynthetic pathway for TP-1161. A cosmid containing the TP-1161 cluster (tpa) was 
isolated from a genomic cosmid library constructed for TFS65-07 and used for further 
studies of tpa gene functions. For heterologous expression, the cosmid was modified 
inserting the C31 integration function and a selective marker, and successfully 
introduced into the genome of Streptomyces coelicolor M512. Heterologous production 
of TP-1161, however, could not be detected in M512. Further studies involving e.g. 
alternative hosts could pave the way for a systematic functional analysis of all genes 
involved in the TP-1161 biosynthesis. 
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INTRODUCTION 
1 INTRODUCTION 
1.1 Antibiotics – a brief historic overview 
 
The modern era of antibiotic chemotherapy started with introduction of penicillin into 
clinical practice in the 1940s (65) for treatment of infectious diseases in humans. 
Penicillin was first discovered in 1928 as a secondary metabolite derived from the 
common mold Penicllium notatum. The discovery of gramicidin in 1939 (29) - the first 
bactericidal agent isolated from a soil-derived bacterium (Bacillus brevis) - initiated the 
systematic isolation and screening of soil bacteria and fungi for new antibiotics. The 
discovery of streptomycin in 1943 (94) put bacteria belonging to the order 
Actinomycetales – the actinomycetes – in the limelight of antibiotic drug discovery. 
Streptomycin was the first compound of a plethora of bioactive secondary metabolites 
derived from members of the genus Streptomyces, which would become established as 
the most prolific bacterial antibiotic producers delivering the majority of antibiotic 
drugs still in use today (11).  
 
In the course of the 1940s and 1950s, most of the today known antibiotic classes, 
including the -lactams, tetracyclines, aminoglycosides and macrolides, were 
discovered and introduced into the clinic (Figure 1.1) (61). With the discovery of the 
streptogramins and quinolones in 1962 this “golden era” of antibiotic drug discovery 
from microbes came to a halt. While the number of new compounds still increased, due 
to production of analogs by chemical derivatization of already known molecules, no 
genuinely new antibiotic class with novel mode of action was licensed during the 
following three decades (1970-2000) (11). It was only in 2000-2003 that two molecules 
belonging to novel antibiotic classes were launched, the chemically synthesized 
linezolid (oxazolidinone) and the bacterial secondary metabolite daptomycin (cyclic 
lipopeptide) (85). 
 
1 
INTRODUCTION 
1942
1943
1947
1949
1952
1955
1957
1961
1962
1955
1983
1967
1982
2000
1987
1997
1990
1999
2000
20032003
Penicillin, the fist -lactam enters the 
market
Chloramphenicol is introduced
First glycopeptide, vancomycin, 
approved
Streptomycin, the first 
aminoglycoside  is discovered
Discovery of rifamycins
Quinolones and streptogramins are 
discovered
1945Tetracyclines are developed
Linezolid, the first oxazolidinone 
class antibiotic is approved  the US
Daptomycin, the first lipopeptide is 
approved
Staphyloccocus aureus shows resistance 
against penicillin
Macrolides enter the market
Isolates of erythromycin-resistant 
staphylococci reported in Japan, 
England, France and the US
Methicillin-resistant Staphyloccocus 
aureus (MRSA) detected in the UK
Penicillin-resistant Neisseria 
gonorrhoeae and Streptococcus 
pneumoniae reported
MRSA develops resistance to 
cephalosporins
Penicillin-resistant Enterococcus 
faecium detected
1970First-generation cephalosporins are 
launched
Vancomycin-resistant enterococci 
detected
Multi-drug resistant Pseudomonas 
aeruginosa and Mycobacterium 
tuberculosis are emerging
First vancomycin-resistant S.aureus strain 
detected in Japan
Linezolid-resistant enterococci are isolated
Community-aquired MRSA recognized as 
emerging pathogen
Linezolid-resistant S. aureus reported
 
 
Figure 1.1. An arms race: the introduction of new antibiotic classes and emergence of 
bacterial resistance (adapted from 36, 81). 
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While the original definition of antibiotics by the soil microbiologist Selman Waksman, 
the discoverer of streptomycin, was strictly limited to microorganism-derived low 
molecular metabolites inhibiting or destroying other microorganisms, contemporary use 
of the term also includes agents derived from other natural sources or compounds of 
synthetic or semi-synthetic origin (60). 
 
1.2 Antibiotic resistance and the urgent need for new drugs 
 
The results of a clinical study of 122 consecutive patients with systemic Staphylococcus 
aureus infection published in 1941 - just before the introduction of penicillin – 
documented 82% mortality, and of the 40 patients who were older than 40 years only 
one recovered (102). The introduction of antibiotic therapy has had a tremendous 
impact on human life expectancy and quality. Bacteria-caused infections such as 
pneumonia, typhus, plague, cholera, syphilis and tuberculosis, once being among the 
leading causes of death around the world, could now effectively be treated with the new 
drugs available.  
 
With widespread and often unwarranted use of antibiotics a new threat began to arise in 
form of the emergence and spread of bacteria resistant to commonly used antibiotics 
(Figure 1.1). While antibiotic resistance determinants are a naturally occurring 
biological phenomenon, especially in antibiotic producers where self-resistance 
mechanisms usually pre-exist coupled to antibiotic biosynthesis pathways, antibiotic use 
favors the spread of resistance mechanisms throughout and across bacterial populations 
(46). Inadequate use, especially the widespread, mostly non-therapeutic application of 
antibiotics (as growth promotants or for prophylactic purposes) in intensive animal 
husbandry, is likely to have had a considerable impact on the pace of resistance 
development (46). 
 
Antibiotics exert selective pressure on a microbial population, allowing the survival of 
only those cells, which have or have acquired resistance to them. The first line of 
defense is the bacterial cell envelope which, especially in Gram-negative bacteria 
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possessing an additional outer membrane, can provide a physical barrier preventing 
antibiotic molecules from entering the cell (116). Other bacterial resistance mechanisms 
can include active efflux or decreased uptake of antibiotics, enzymatic inactivation of 
the antibiotic molecule, modification of the cellular target (e.g. by mutation or enzyme-
mediated decoration), overproduction of the target or bypass of the targeted metabolic 
pathway (101). Resistance determinants can be readily acquired by horizontal transfer 
of mobile genetic elements such as plasmids, bacteriophages, transposons, gene 
cassettes and integrons through transduction, transformation and conjugation processes 
(9). 
 
However, back in the golden era of antibiotic discovery, the advent of penicillin-
resistant Staphylococcus aureus strains only a few years after introduction of penicillin 
(103) was met with little concern due to the steady supply of new drugs and the 
development of a plethora of improved analogs of already known molecules. But also 
the introduction of semi-synthetic analogs such as the penicillin-derived methicillin in 
the 1960s, which had been developed to confront -lactamase producing resistant 
pathogens, was soon followed by the emergence of methicillin-resistant staphylococci 
(Figure 1.1) (50). Today, a host of “bad bugs” including methicillin-resistant Staph. 
aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), and 
fluoroquinolone-resistant Pseudomonas aeruginosa species (16) have taken over 
hospital and community settings and with emerging pandrug-resistant bacteria (resistant 
to all available antibiotics) therapeutic options are often set back to pre-antibiotic times 
with no effective therapy available (70).  
 
Although antibiotic resistance has been a problem ever since their introduction to 
human therapy, it is the increase in number, diversity and range of resistant microbes 
that causes the precarious current situation. The spectrum of human pathogens has 
dramatically changed and previous commensals like Staph. aureus, enterococci and 
Escherichia coli have become potent pathogens through acquisition of multiple 
antibiotic resistances and simultaneous increase in virulence (2). A whole new 
generation of opportunistic pathogens such as pandrug-resistant Gram-negative strains 
of Acinetobacter baumannii, P.aeruginosa, Stenotrophomonas maltophilia and 
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Burkholderia cepacia are now threatening an ever growing population of susceptible 
patients with compromised immune systems (116). 
 
Despite the alarming development, the list of new antibacterials with novel modes of 
action is short. Since 2006, only one new antibacterial agent (doripenem) has been 
approved for therapy in USA and the number of potential candidates in clinical trials, 
with only three compounds in advanced development, is very meager (16).  
 
1.2.1 Sources for new drugs 
 
Modern drug discovery is based on three major sources: natural products, semi-
synthetic derivatives of natural products and synthetic compounds derived from 
combinatorial chemistry libraries. The vast majority of clinically relevant antibiotics in 
use today are natural products or compounds derived thereof. Over the past 20 years, 
60% of the 877 drugs that have reached the market were natural products (61). Despite 
these numbers, most major pharmaceutical companies have diverted their drug 
discovery programs away from natural product-based research. The availability of high-
throughput-screening (HTS) technology in form of automation and robotization in the 
1990s in addition to high expectations from identifying new molecular targets from the 
rising number of bacterial genome sequences, caused a shift away from natural product-
based research efforts in favor of establishing HTSs of combinatorial libraries of 
synthetic compounds (85).  
 
Developed as an alternative to the time- and resource-heavy process of empirical natural 
product-based drug discovery, in silico (computational) approaches have become an 
emerging trend in lead identification and optimization. In silico approaches are based on 
virtual screening of virtual or existing chemical structure libraries to identify potential 
drug leads which are then chemically synthesized and subjected to a biological 
screening (52).  
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Commonly used computational approaches in drug design and development include (i) 
ligand-based design (pharmacophore modeling and 3D similarity searches), (ii) 
structure (target)-based design (“docking”) and (iii) quantitative structure-
activity/property relationships (QSAR/QSPR) for e.g. computational predictive 
toxicology (52). Both, ligand-based screening and structure (target-) based design are 
based on previous knowledge about active ligands and/or three-dimensional structure 
information of target receptors (e.g. x-ray crystallographic or NMR data) (52). In the 
process of “docking”, libraries of potential ligands are generated in silico, selected for 
optimal positioning in the receptor binding site and scored for potential activity. Top-
scoring compounds can then be synthesized and evaluated by experimental testing (51). 
Successful examples of this approach include the discovery of novel DNA gyrase 
inhibitors using 3D structural information of the targeted ATP binding site (15). While 
target-based approaches are based on the principle of complementarity, ligand-based 
screening approaches rely on similarity (69). Ligand-based virtual screenings rank 
potential novel ligands based on 3D similarity searches or on pharmacophore pattern 
matching (87). 
 
1.2.2 Natural products vs. chemical synthesis 
 
Payne et al. described in a review from 2007 the outcome of a seven-year antibacterial 
drug discovery program run at GlaxoSmithKline. The program consisted of a genomics-
derived, target-based screening of synthetic compound libraries aiming at finding new 
classes of antibiotics with preferably novel modes of action (89). In the course of the 
screening more than 300 genes representing potential new antibacterial targets were 
evaluated and promising candidates investigated in 70 HTS campaigns. The outcome of 
the biochemical screenings of individual bacterial targets as well as additionally set-up 
whole-cell antibacterial screenings were described as “disappointing” with 
“unsustainably low” success rates (89). The authors concluded that screening 
approaches based on synthetic libraries and isolated biological targets are inadequate for 
the discovery of novel antibacterial leads (89). 
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Natural products have several advantages over compounds derived from combinatorial 
synthesis approaches. While synthetic molecules can be rapidly generated by 
combinatorial chemistry from sets of smaller chemical entities, their structural diversity 
is limited, often due to lack of chiral centers, aromatic rings, oxygen-containing 
substituents and structural rigidity (31). The diversity of natural products on the other 
hand can provide physicochemical properties such as specific interactions with often 
multiple biological targets that are hardly found in molecules derived from 
combinatorial synthesis (84). As metabolic products of living organisms, natural 
product-derived antibiotics have the genuine advantage of having evolved to be active 
in target cells in vivo, abandoning a major obstacle of target-based approaches – the 
conversion of in vitro hits into whole-cell active leads (6). 
 
However, natural product-based drug discovery is a complex, time-consuming and 
expensive endeavor. Compared to drugs for long-term treatment of chronic illnesses, 
antibiotics (especially antibacterials) do not present commercial incentives to the 
pharmaceutical industry (84). It is estimated that the entire process from the discovery 
of a new drug to the development, pre-clinical research to clinical trials takes on 
average more than a decade with costs exceeding 800 million USD (28). High 
investments, short therapy times and the limited lifespan of antibiotics due to emerging 
resistances have led to decreased or abandoned antibacterial drug discovery efforts in 
most of the major pharmaceutical companies, leaving the field mainly to academia and 
smaller biotechnology firms (84). 
 
1.3 Actinomycetes – major antibiotic producers 
 
Traditionally, it has been mainly terrestrial bacteria and predominantly Gram-positive 
bacteria of the order Actinomycetales, the actinomycetes, that have been the focus of 
extensive screening efforts for new bioactive natural products. Actinomycetes have 
been the source for numerous important therapeutic drugs including antibacterials, 
antifungals, neostatics, antiparasitics and immunosuppressants and represent 
undoubtedly the most prolific antibiotic producers. 45% of all known bioactive natural 
7 
INTRODUCTION 
products are produced by actinomycetes (11), including more than 50% of all microbial 
antibiotics discovered so far. Members of the genus Streptomyces account for 70-80% 
(11) of the about 3000 currently characterized actinomycete antibiotics (111). However, 
the occurrence of these bacteria is by far not limited to soil environments. 
Actinomycetes are ubiquitous organisms with wide physiological and morphological 
diversity and have been isolated from all kinds of terrestrial and aqueous habitats where 
they can exist as free-living bacteria as well as pathogens (96) or in symbiotic 
associations with plants (10) and insects (25, 92) or as endophytes (7).  
 
The development of specific enrichment and cultivation techniques as well as logistical 
and technological advances (e.g. unmanned submersibles) have extended sampling 
ranges and studies of actinomycetes to previously inaccessible locations such as the 
deep-sea ocean environments (Table 1.1) (88). It is also interesting to note that despite 
extensive screening of terrestrial isolates, soil samples have still only been taken from a 
minute fraction of the surface of the entire globe (6). Consequently, the taxonomic 
diversity even within the well-studied group of terrestrial actinomycetes is likely to be 
far from exhausted (111).  
 
1.3.1 Marine actinomycetes – a promising source for new drug discovery 
 
Investigations of marine micro- and macroorganisms such as mollusks, bryozoans, 
sponges and bacteria have yielded numerous pharmacologically interesting compounds 
during the last years, especially in the group of anticancer drugs (79). The first “drugs 
from the deep” included ziconotide, a peptide isolated from a tropical cone snail and 
launched in 2004 as “Prialt” for treatment of chronic pain, and the antitumor compound 
trabectedin originating from a tropical sea-squirt and approved by the EU in 2007 (79). 
Marine macroorganisms clearly represent a rich source for novel bioactive molecules 
(13), however the development of new pharmaceuticals relies on a sustainable supply 
with sufficient quantities of potential drug leads. Low abundance of the natural producer 
and/or low concentrations of the molecule of interest (as it is usually the case for marine 
macroorganisms) are therefore problematic. Bacteria, on the other hand, are a much 
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more amenable source for drug discovery and upscaled biotechnological production of 
interesting compounds (41). Furthermore, it has been demonstrated that many 
compounds which had been originally derived from marine macroorganisms were in 
reality produced by their bacterial symbionts (79).  
 
The most productive marine bacterial phyla are represented by members of the 
Cyanobacteria and Actinobacteria; contributing 220 and 256 compounds, respectively, 
to the 659 marine bacterial compounds described over a 10 years period up to 2008 
(114). As a response to increasing re-discovery rates of already known actinomycetes 
and their antibiotics in soil-derived libraries, isolation efforts were increasingly focused 
on actinobacterial diversity in the marine environment (66, 75). Although the oceans 
represent a largely untapped resource for biodiversity, the cultivation of marine-derived 
bacteria still represents a considerable challenge. While it is estimated that less than 
0.3% of soil bacteria can be cultivated in common media, this fraction drops to 
0.00001% for water-associated microorganisms (3). 
 
Actinomycetes have been isolated from the most diverse marine habitats ranging from 
the sea-surface microlayer (39), over shallow-water sediments (17, 46) to extreme 
environments such as deep sea sediments (88) and hydrothermal vents (106) (Table 
1.1). They have been found associated with marine micro- and macrofauna, marine 
invertebrates like sponges and vertebrates including fishes (109). The origin of marine 
populations of actinomycetes had long been disputed. Terrestrial isolates are known to 
produce resistant spores which can be washed into the seas where they would stay 
viable for years,  and thus it had been suggested that marine actinomycete isolates are a 
mere result of terrestrial contamination (38).  
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Table 1.1. Examples of “rare” marine actinomycete genera identified by culture and 
molecular techniques in different marine habitats (adapted from 109). 
Actinomycete genus 
 
Species affiliation 
 
Source 
 
Actinomadura A. formosans, A. fulvescens Japan Trench, Canary Basin, fjord site. 
Sub-tropical sediment 
Actinosynnema Actinosynnema sp. IM-1402 Deep sea sediment 3800 m 
Brachybacterium B. arcticum Barcelona neuston 
Dietzia D. maris Japan Trench, Canary Basin, fjord site. 
Deep sea sediment 3800 m. Barcelona 
neuston 
Frigoribacterium Frigoribacterium sp. 301 Deep sea sediment 3800 m 
Geodermatophilus Geodermatophilus sp. BC509, IM-1092 Deep sea sediment 3800 m 
Kineococcus-like Kineococcus-like AS2978 Deep sea sediment 3800 m 
Kitasatospora Kitasatospora sp. IM-6832 Deep sea sediment 3800 m 
Microbacterium M. kitamiense, M. esteraromaticum Japan Trench, Canary Basin, fjord site. 
Barcelona neuston. Wadden Sea 
aggregate 
Nocardioides Nocardioides sp. V4.BO.15, N. jensenii Deep sea sediment 3800 m. Barcelona 
neuston 
Nocardiopsis N. dassonvillei Ovaries of Pufferfish, Bohai Sea of 
China 
Pseudonocardia P. alaniniphila, P. aurantiaca, P. alnii Deep sea sediment 3800 m 
Rhodococcus R. fascians, R. koreensis, R. opacus,  
R. ruber, R. tsukamurensis, R. zopfii 
Deep sea sediment 3800 m, Pelagic 
clay 
Salinispora S. arenicola, S. tropica Sub-tropical sediment 
Serinicoccus S. marinus Sea water East Sea, Korea 
Tsukamurella T. inchonensis Deep sea sediment 3800 m 
Turicella T. otitidis Deep sea sediment 3800 m 
Verrucosispora Verrucosispora sp. AB-18-032, IM-6907 Japan Trench, Canary Basin and fjord 
site 
Williamsia W. maris, W. marianensis Japan Trench, Canary Basin and fjord 
site 
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Numerous isolations and characterization of marine-derived actinomycetes, however, 
have proved that indigenous marine actinobacterial species indeed exist, and new genera 
or groups of marine actinomycetes have been described for more than six different 
families within the order Actinomycetales (33). The first marine actinomycete, 
Rhodococcus marinonascens, was described in 1984 (44) and in 2005 the first seawater-
dependent marine actinomycete, Salinispora, was reported (67). It has been shown that 
marine actinomycete species are physiologically and phylogenetically distinct from 
their terrestrial relatives, they can possess specific adaptations  to the ocean 
environment (e.g. to high salinity and pressure) and were found to represent a rich 
source for novel, chemically diverse bioactive secondary metabolites with potential 
applications in antimicrobial and anticancer therapy (18, 19, 49, 68, 109). The 
salinisporamides (32, 93, 115), abyssomicins (94), proximicins (34) and marinomycins 
(58) are amongst a variety of new marine-actinomycete derived products with 
significant biological activity and potential applications as anticancer and antibacterial 
drugs (see Table 1.2).  
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Table 1.2. Novel metabolites produced by marine actinomycetes discovered during the 
period 2003–2005 ((adapted from 59)). 
Compound 
 
Actinomycete producer 
 
Biological activity 
 
Abyssomicins Verrucosispora sp. Antibacterial
Aureoverticillactam Streptomyces aureoverticillatus Anticancer
Bonactin Streptomyces sp. Antibacterial; antifungal 
Caprolactones Streptomyces sp. Anticancer
Chandrananimycins Actinomadura sp. Antialgal; antibacterial; anticancer; antifungal
Chinikomycins Streptomyces sp. Anticancer
Chloro-dihydroquinones Novel actinomycete Antibacterial; anticancer 
Diazepinomicin 
(ECO-4601) 
Micromonosproa sp. Antibacterial; anticancer; anti-inflammatory 
3,6-disubstituted indoles Streptomyces sp. Anticancer
Frigocyclinone Streptomyces griseus Antibacterial
Glaciapyrroles Streptomyces sp. Antibacterial
Gutingimycin Streptomyces sp. Antibacterial
Helquinoline Janibacter limosus Antibacterial
Himalomycins Streptomyces sp. Antibacterial
IB-00208 Actinomadura sp. Anticancer
Komodoquinone A Streptomyces sp. Neuritogenic activity
Lajollamycin Streptomyces nodosus Antibacterial
Marinomycins ‘Marinispora’ Antibacterial; anticancer 
Mechercharmycins Thermoactinomyces sp. Anticancer
MKN-349A Nocardiopsis sp. Unknown biological activity 
Salinosporamide A  
(NPI-0052) 
Salinispora tropica Anticancer 
Sporolides Salinispora tropica Unknown biological activity 
Trioxacarcins Streptomyces sp. Antibacterial; anticancer; antimalarial 
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1.3.2 Bioprospecting of marine actinomycetes for new antibiotics 
 
Prospecting the natural biodiversity – bioprospecting - aims to discover new natural 
products, genes or proteins with biomedical or biotechnological application potential. 
Nearly all antibiotics have been discovered in empirical approaches using simple 
antagonistic assays against different bacteria by assessing the inhibition of growth of 
different target organisms by whole broths or extracts of microbial fermentations (101). 
Despite major technical advances in instrumentation and automation, activity-based 
drug discovery is essentially very similar to the screening approaches used by Fleming 
and others in the very beginning of microbial drug discovery (101). A scheme showing 
bioprospecting for antibiotics in marine-derived actinomycete bacteria is outlined in 
Figure 1.2. 
 
Many different methods to increase the efficiency of each of the described steps have 
been developed. New cultivation techniques have improved culturability and isolation 
of previously undescribed bacterial species in pure culture. Examples include high-
throughput cultivation under high dilution-to-extinction culturing conditions for 
recovery of slow-growing bacterial strains (23) or microencapsulation of single cells 
combined with flow cytometry (119). To increase the efficiency of fermentation 
extraction and to stabilize produced secondary metabolites, cultivation can be 
performed with resins and early mass spectral data and structural information - crucial 
for dereplication and identification of potentially novel compounds - can be obtained 
using liquid chromatography (LC) coupled with MS, UV and NMR analyses (78). 
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Figure 1.2. Bioprospecting of marine actinomycetes for new antimicrobials. 
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1.4 The influence of microbial genomics on drug discovery 
 
The development of new sequencing technologies (73) has led to plummeting 
sequencing costs and bacterial genome sequencing and mining is becoming a common 
tool in drug discovery. More than 1000 completed bacterial genome sequences are now 
available at the NCBI Genome Database (http://www.ncbi.nlm.nih.gov/ 
genomes/lproks.cgi) and advances in understanding microbial genetics and processes 
involved in secondary metabolite biosynthesis have made it possible to identify and 
analyze numerous gene clusters for biosynthesis of new bioactive compounds, including 
antibiotics.  
 
Bacteria with larger genomes have turned out to be an especially rich source for 
secondary metabolite pathways. A comparison of 115 completed prokaryotic genome 
sequences revealed a disproportionate increase in genes for secondary metabolism and 
regulation in large genomes compared to medium- and small-sized genomes (56) and 
this trend is especially obvious in the actinomycetes. Genome sequencing efforts have 
yielded to date more than 70 completed and annotated actinobacterial genome 
sequences, the majority of which represent members of the Actinomycetales and it has 
been shown that the most prolific secondary metabolite producers generally have rather 
large genomes (>5 Mb) (82). Members of families such as the Streptomycetaceae, 
Micromonosporaceae and Pseudonocardiaceae often possess more than 20 gene 
clusters for secondary metabolite biosynthesis yielding a diverse array of natural 
products including polyketides, non-ribosomal peptides, bacteriocins and lantibiotics 
(82).  
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Table 1.3. Actinomycete species with completed genome sequences and predicted 
number of secondary metabolite gene clusters (82). 
Actinomycete species 
Genome size 
(chromosome) 
Number of 
predicted clusters 
Number of orphan 
pathways 
Streptomyces coelicolor A3(2) 8667507 29 14 
Streptomyces avermitilis MA-4680 9025608 37 24 
Streptomyces griseus IFO 13350 8546929 36 27 
Saccharopolyspora erythraea 
NRRL2338 
8212805 27 24 
Salinispora tropica CNB-440 5183331 19 14 
Salinispora arenicola CNS-205 5786361 30 25 
 
The complete 9 Mb genome of Streptomyces avermitilis was published in 2003 (47). 
The strain was known for production of the polyketide macrolides avermectin and 
oligomycin, and the genome sequence revealed a total of 37 secondary metabolite gene 
clusters, including 13 PKS (polyketide synthase), 8 NRPS (non-ribosomal synthetase), 
various terpenoid, siderophores and bacteriocin encoding clusters (Table 1.3). Summed 
up in size, these clusters represent almost 7% of the genome of S. avermitilis (82). The 
genomes of two marine actinomycete species, Salinispora tropica CNB-440 and 
Salinispora arenicola CNS-205, though smaller in size than that of S. avermitilis, 
contain an even higher percentage of genes involved in secondary metabolite 
biosynthesis. Almost 9% of the Salinispora tropica genome consists of secondary 
metabolite encoding clusters, while Salinispora arenicola devotes more than every tenth 
gene to secondary metabolite biosynthesis (82). 
 
1.4.1 Genome mining and orphan pathways for secondary metabolite 
biosynthesis 
 
Considering the wealth of available genome sequences, mining microbial genomes is 
becoming a powerful tool in drug discovery. Systematic identification of gene clusters 
for natural product biosynthesis using bioinformatics tools (e.g. homology-driven 
searches for conserved protein motifs) has for many bacteria revealed a massive gap 
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between the number of predicted biosynthetic gene clusters and known products (Table 
1.3). So-called “orphan” pathways, for which no biosynthetic product has been reported, 
represent a rich source for drug discovery and different strategies can be applied to 
identify the metabolic products of cryptic gene clusters. In the genomisotopic approach, 
precursor amino acids, which have been predicted to be specifically incorporated into 
the final product based on genomic information, are isotopically labeled and tracked 
using NMR techniques (21). A second method based on gene disruption experiments 
followed by a comparison of the secondary metabolite spectra of mutant and wild type 
strains, can reveal the encoded product and has the simultaneous advantage of 
delivering a functional proof for the corresponding gene cluster (21). The comparative 
metabolite profiling strategy can be equally well combined with heterologous 
expression approaches, where metabolite spectra of the parental host are compared to 
those of recombinants (21). 
 
How genome mining for new natural products can be successfully applied even in the 
absence of complete genome sequence information was demonstrated by Ecopia 
Biosciences with the discovery and isolation of the novel antifungal ECO-02301 from 
Streptomyces aizunensis NRRL B-11277 (71). For multimodular biosynthetic systems 
such as PKSs and NRPSs, the order of biosynthetic steps can often be directly derived 
from the gene organization in the biosynthetic gene cluster. Shot gun DNA sequencing 
of S. aizunensis was used to identify genome sequence tags (GSTs) predicted to be 
involved in the biosynthesis of secondary metabolites. Selected tags were used as 
probes to isolate cosmids from a genomic library and a gene cluster of 35 open reading 
frames predicted to include a large type I PKS was isolated and sequenced. Information 
on chemical novelty, approximate mass and UV absorbance could be derived from the 
predicted structure of the final product. In previous fermentation studies, S. aizunensis 
had only been reported to produce bicyclomycin. To obtain production of ECO-02301, 
the strain was grown in nearly 50 different media followed by fermentation extract 
analysis using LC-MS. Activity-guided fractionation identified several antifungal 
fractions with predicted masses and UV absorbance and finally led to isolation of the 
novel compound (71). 
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1.4.2 Metagenomics 
 
Obtaining genome sequence information in most cases still requires cultivable 
microorganisms in pure culture. However, only a minute fraction of the overall bacterial 
diversity has been cultivated under laboratory conditions (3). Metagenomics involves 
the creation of libraries of DNA directly isolated from environmental sources (soil, 
seawater etc.) followed either by sequence or expression analysis in suitable 
heterologous hosts (98). Culture-independent approaches can access the true microbial 
diversity by analyzing the collective gene pool of all organisms present in a particular 
sample. However, to target entire functional operons, metagenomic approaches rely 
heavily on large capacity cloning vectors like cosmids or BACs and suitable hosts for 
heterologous expression of the recombinant products as well as suitable protocols to 
introduce DNA into heterologous hosts (37).  
 
Cloning and expression studies focused on the soil metagenome have allowed isolation 
of a number of small bioactive molecules including violacein, indirubin and the 
turbomycins (63 and references cited therein). Using E. coli as host for both cloning and 
expression can considerably limit the number of possible hits (see also 1.4.4) (26), 
therefore the transfer of libraries to a variety of surrogate hosts can be advantageous. 
Craig et al. chose a rather unusual expression host, Ralstonia metallidurans, for 
screening a soil DNA library for the production of pigments and antibiotics (24). They 
succeeded in isolating two novel metabolites and further studies indicated that these 
compounds were produced as a result of interactions between host enzymes and the 
heterologously expressed metabolites (24). 
 
1.4.3 OSMAC – One Strain MAny Compounds 
 
OSMAC is based on the fact that microorganisms often have the biosynthetic potential 
to produce many different compounds in dependence on changing environmental 
conditions. The approach relies on rather random variation of cultivation conditions to 
trigger the production of multiple secondary metabolites by a single organism (14). 
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Simple variations of media composition, pH value, aeration, cultivation temperature, 
culture vessel or the addition of enzyme inhibitors can lead to dramatic differences in 
secondary metabolite profiles. Bode et al. were able to detect over 100 compounds 
representing more than 25 structural classes when using this approach with only six 
microorganisms including four Streptomyces strains and two fungi (14). Extensions of 
the OSMAC approach, e.g. for triggering expression of cryptic secondary metabolite 
clusters, are practically unlimited. Examples range from addition of cytotoxic 
compounds to fermentation media (22) to mixed fermentations of bacteria and/or fungi 
leading to the discovery of a range of novel bioactive metabolites (90).  
 
1.4.4 Heterologous production of natural products 
 
Efficient isolation, characterization and modification of natural products require 
sufficient quantities of the molecule of interest. Therefore, heterologous production of 
natural products can be an alternative to lengthy fermentation optimization involving 
the natural producer or costly total synthesis approaches (37). Furthermore, 
heterologous expression can be used for functional confirmation of biosynthetic gene 
clusters and as a platform for combinatorial biosynthesis. It can also be applied to 
trigger expression and analyze the products of cryptic gene clusters (39). 
 
A number of challenges are connected to the production of natural products in 
heterologous hosts. As already mentioned, moving entire biosynthetic gene clusters 
from the natural producer to the heterologous hosts requires suitable large-capacity 
vectors, as well as established gene transfer protocols (37). The choice of the 
heterologous host is crucial and many factors can determine if expression is successfully 
achieved at satisfactory levels. These factors include growth characteristics of the 
heterologous host, precursor availability, codon usage, efficiency of 
transcription/translation and posttranslational modifications of pathway-specific 
enzymes (37). For easy detection of expressed compounds, a host background low in 
secondary metabolites production is desirable. Strains closely related to the native 
producer are often likely to provide most of the desired features (37). 
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Successful examples of heterologous expression of a range of natural products are 
compiled in Table 1.4, where expression of entire biosynthetic gene clusters has been 
achieved based on integrative or replicative cosmid vectors, combinations thereof, or 
modified BAC vectors equipped with mobilization functions to allow intergeneric 
transfer between E. coli and Streptomyces strains (37). 
 
Table 1.4. Antibiotics successfully produced in heterologous hosts by introducing entire 
biosynthetic gene clusters (adapted from 37). 
Compound Class Native producer Sizea Vector usedb Host strain Yieldc 
Actinorhodin PKS II S. coelicolor A3(2) ~32.5 pIJ922rep S. parvulus 100 
Blasticidin S Peptidyl 
nucleoside 
S. griseochromo-
genes 
20 pOJ446rep S. lividans 
TK24 
100 
Cinnamycin Lantibiotic S. cinnamoneus 17.1 pOJ436int S. lividans 1326 NR 
Clorobiocin Amino- 
coumarin 
S. roseochromo- 
genes var. oscitans 
DS 12976 
34 SuperCos1int S. coelicolor 
M512 
104 
Daptomycin NRPS S. roseosporus 128 pStreptoBACVint S. lividans 
TK64 
2 
Epothilone PKS-
NRPS 
Sorangium 
cellulosum SMP44 
56 SCP2rep  
pSET152int 
S. coelicolor 
CH999 
>250 
Patellamides Peptide Prochloron sp. <20 pPAC-S1, 
pPAC-S2 
E. coli DH10B NRd 
Soraphen A PKSI Sorangium 
cellulosum Soce26 
67.5 pTBKint 
pTBBHint 
pTUErep 
S. lividans ZX7 <0.2 
Thiocoraline NRPS Micromonospora 
sp. ML1 
53 pARPint S. lividans 
TK24,  
S. albus J1274 
NR 
 
a size in kb; b replicative (rep) or integrative (int); c % of wildtype production; d uncultured native 
producer (only heterologous production reported), NR: not reported 
 
Due to its excellent growth characteristics and genetic amenability, E. coli would be the 
first choice candidate for heterologous production of natural products. However, the 
expression of antibiotic biosynthesis clusters, especially of PKS- and NRPS-based 
systems, is met with a number of challenges in E. coli such as largely different GC-
contents, promoter recognition problems, precursor availability (e.g. methylmalonyl-
CoA) and essential posttranslational modifications (e.g. activation of PKS and NRPS 
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through phosphopantetheinylation) (37). To tackle the obstacles posed by E. coli hosts, 
engineered E. coli strains have been developed with plasmid-based copies of tRNA 
genes to overcome codon bias problems via efficient translation of rare codons. To 
ensure posttranslational activation of PKS and NRPS systems, strains carrying a 
chromosomally integrated phosphopantetheinyl transferase gene derived from Bacillus 
subtilis (110) have been constructed.  
 
For expression of actinomycete-derived secondary metabolite gene clusters, 
Streptomyces strains including the model organisms S. lividans and S. coelicolor, but 
also S. albus, are still considered the most robust hosts (37). The industrial avermectin 
producer S. avermitilis has recently been engineered for heterologous production of 
secondary metabolites by genome minimization (55). The deletion of non-essential 
genes (reducing the 9.02 Mb linear chromosome by more than 1.4 Mb) yielded a host 
devoid of any major endogenous secondary metabolites. The suitability of this strain for 
high-level heterologous production of natural products was demonstrated by successful 
expression of exogenous antibiotic biosynthetic gene clusters including those for 
biosynthesis of streptomycin and cephamycin C (55). 
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1.5 Peptide-based antibiotics and biosynthetic mechanisms 
 
Antimicrobial peptides are ubiquitous in nature and are produced by all kinds of 
organisms ranging from bacteria and fungi to plants and higher eukaryotes. They 
comprise a variety of structural classes including established antibiotic classes such as 
the -lactams, glycopeptides and lipopeptides as well as lantibiotics (lanthionine-
containing antibiotics) and other bacteriocins. The bacterial peptide-based antibiotics 
vancomycin and teicoplanin have been in use for treatment of Gram-positive bacterial 
infections for decades (108) and the lantibiotic nisin is widely used as a food 
preservative (40). 
 
 
 
Figure 1.3. Examples of peptide-based antibiotics (ribosomally and non-ribosomally 
synthesized) (adapted from 83). 
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The synthesis of peptide-based antibiotics in bacteria is generally mediated in two 
different ways: ribosomally and non-ribosomally. Non-ribosomal synthesis is 
accomplished by non-ribosomal peptide synthetases (NRPS) and the products of these 
multimodular assembly lines can undergo further enzymatic modifications yielding e.g. 
glyco- and lipopeptides like vancomycin and daptomycin (Figure 1.3) (83). 
 
Common to all ribosomally synthesized peptide antibiotics is that they are synthesized 
as (inactive) precursors from chromosomally encoded precursor peptide genes. 
Therefore, the composition of these peptides is limited to the 20 proteinogenic amino 
acids (plus selenocysteine), as opposed to NRPS-mediated biosynthesis where more 
than 200 non-proteinogenic amino acids can be used as building blocks (83). The native 
precursor peptides commonly undergo a series of posttranslational tailoring reactions 
introducing conformational rigidity and proteolytic stability. Examples of such tailored 
ribosomal peptides include the microcins, lantibiotics and patellamides (Figure 1.3). 
Common modifications in these molecules include dehydration of amino acids, 
exemplified by formation of dehydroalanine and dehydrobutyrine groups present in 
lantibiotics, and heterocyclization reactions, yielding e.g. the 5-membered aromatic 
heterocycles in microcins and patellamides (cyanobactins) (83).  
 
1.5.1 Thiopeptide antibiotics 
 
In another class of ribosomally synthesized peptide antibiotics, the thiazolyl peptides 
(thiopeptides), combinations of tailoring reactions from lantibiotic, microcin and 
cyanobactin biosynthesis can be found. Thiopeptide antibiotics have been isolated 
predominantly from different Streptomyces strains, but also from a range of other Gram-
positive bacteria including  Micrococcus and Bacillus (5).The defining feature of this 
rather large antibiotic class is the overall macrocyclic structure, which is centered by a 
characteristic 6-membered nitrogen-containing heterocycle (Figure 1.4) (5). According 
to the oxidation state of this heterocycle, five different subclasses (series a-e) are 
distinguished comprising in total more than 80 distinct structural entities. Amino acids 
in thiopeptides are usually heavily modified to multiple thiazole and (methyl)oxazole 
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groups as well as dehydro amino acids in form of dehydroalanine (dha) and 
dehydrobutyrine (dhb) (5). 
 
Thiostrepton A
Thiocillin INosiheptide
Berninamycin A
A10255
B: R=Et     E: R=iPr     G: R=Me
 
 
Figure 1.4. Examples of thiopeptide antibiotics: thiostrepton A (series b), berninamycin 
A, thiocillin I and A10255 factors (series d) and nosiheptide (series e) (adapted from 5). 
 
Micrococcin, isolated in 1948 from a Micrococcus strain was the first thiopeptide to be 
discovered (104). As series d thiopeptide it is a representative of the by far largest series 
with more than 50 different compounds including other well-known members like the 
thiocillins and the amythiamicins. All series d compounds are characterized by a tri-
24 
INTRODUCTION 
substituted pyridine domain, a single peptide macrocycle and a side chain consisting of 
multiple dehydrated residues (5). Series a and b molecules such as thiostrepton and 
siomycin are defined by quinaldic acid-containing bicyclic frameworks and central 
piperidine or dehydropiperidine heterocycles. A tetra-substituted piperidine domain is 
the defining feature of series e thiopeptides (e.g. nosiheptide, nocathiacin) and like 
series a/b compounds they usually have a backbone consisting of at least two peptide 
macrocycles (5). 
 
The biosynthetic route which leads from plain ribosomally synthesized precursor 
peptides to the tailored molecules has been unraveled only recently (53, 64, 80, 113). 
The thiopeptide backbone derived exclusively of proteinogenic amino acids is 
transformed in a series of conserved posttranslational modifications through the action 
of a set of unique enzymes, most of which have distant homologs involved in the 
biosynthesis of lantibiotics and cyanobactins. Cyclodehydratases in combination with 
dehydrogenases mediate cyclization of cysteine, serine and threonine side chains against 
the preceding carbonyl group and oxidize the resulting thiazoline, oxazoline and 
methyl-oxazoline products to aromatic thiazoles and (methyl)oxazoles (Figure 1.5A) 
(83). Dehydration of serine and threonine residues through the action of dehydratases 
similar to those involved in lantibiotic biosynthesis yields dha and dhb, respectively 
(Figure 1.5B).  
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Figure 1.5. Typical posttranslational modifications during thiopeptide maturation. A) 
Two-step formation of aromatic heterocycles by cyclodehydration and FMN-dependent 
dehydrogenation. B) Formation of dehydroalanine and dehydrobutyrine from serine and 
threonine residues. 
 
The exact mechanisms and enzymes that mediate the formation of the characteristic 
central 6-membered heterocycle remain to be verified, but feeding studies have shown 
that it arises from two dehydroalanine groups (derived from serine) and a neighboring 
cysteine carboxyl group (76). Cyclization of these residues could then yield a 
dehydropiperidine intermediate which is suggested to be the common basis for 
thiopeptides in all groups (118). Dehydration of dehydropiperidine would then give rise 
to the pyridine series, and further hydroxylation would yield the hydroxypiperidine 
thiopeptides. Piperidine rings can be obtained through reductive conversion from 
dehydropiperidine (118).  
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1.5.2 Thiopeptides – biological activities 
 
Inhibition of bacterial protein synthesis is a very common mode of action employed by 
the majority of existing antibacterial classes (84). Aminoglycosides and tetracyclins, for 
example, bind to the decoding site (A-site) within the bacterial 16S rRNA of the 30S 
ribosomal subunit and interfere with translational fidelity by causing misincorporation 
of amino acids. Macrolide antibiotics, streptogramins, chloramphenicol and the 
oxazolidinones all bind to the 23S rRNA at the peptidyl-transferase center (PTC) and 
inhibit peptide bond formation (45).  
 
Also thiopeptides act on the bacterial ribosome inhibiting the translational machinery. 
Molecular targets include both ribosomal RNA (rRNA) and ribosomal proteins at the 
so-called GTPase associated center on the 50S ribosomal subunit (8). The binding sites 
of thiopeptides were shown to be distinct from those exploited by other translational 
inhibitors and as a result no cross-resistance to existing antibiotics has been found so far 
(8). Thiopeptides most commonly inhibit processes involved in peptide elongation and 
two different mechanisms are employed to achieve this inhibition: i) interference with 
translocation through direct binding to a complex of 23S rRNA and ribosomal protein 
L11 (5, 42) and ii) binding to elongation factor Tu (EF-Tu) (80). 
 
Both, thiostrepton and micrococcin bind to the L11-binding region on the 23S rRNA at 
overlapping sites but with different effects (8). The GTP-bound form of elongation 
factor G (EF-G) promotes translocation of the ribosome along the mRNA by one codon 
(20). Thiostrepton stabilizes a ribosome conformation which is incompatible with 
EF-G·GTP binding and thus inhibits GTP hydrolysis. Binding of micrococcin to the 
same region promotes GTP hydrolysis and induces a more rapid dissociation of 
EF-G·GDP from the ribosome (20). 
 
A second mechanism in form of direct binding to EF-Tu rather than the ribosome is 
employed by monocyclic thiopeptides including GE2270 and the thiomuracins. The 
GTP-bound form of EF-Tu mediates recognition and transport of aminoacyl tRNAs to 
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the mRNA codon in the A-site of the bacterial ribosome (5). Binding to EF-Tu or 
EF-TuGTP blocks the binding site for aminoacyl(aa)-tRNAs and prevents the 
formation of an EF-Tu·GTP·aa-tRNA ternary complex. Consequently, tRNAs cannot be 
delivered to the ribosome and the elongation cycle is interrupted (4). 
 
The biological activity of thiopeptides is not limited to their antibacterial properties. 
Anti-cancer, antimalarial and immunosuppressive effects of thiopeptide antibiotics have 
been described. Thiostrepton and siomycin induce apoptosis in neuroblastoma, 
leukemia and liver cancer cells by inhibiting the activity of transcription factor FoxM1, 
a key positive regulator of the cell cycle. In addition to inhibition of its transcriptional 
activity, they also cause downregulation of FoxM1 expression (12, 57).  
 
Growth inhibition of the malaria parasite Plasmodium falciparum has been reported for 
thiostrepton and micrococcin. High similarity between bacterial 70S ribosomes and the 
mitochondrial or apicoplast ribosomes of the eukaryotic parasite are suggested as basis 
for this activity (72, 95) and new semisynthetic derivatives of thiostrepton have been 
developed which even employ a dual mode of action by targeting both the apicoplast 
ribosomes and the 20S proteasome in parallel (99). Immunomodulating effects by 
suppression of B- and T-cells have been reported for siomycin, thus indicating a 
potential for development of this compound for treatment of antibody-mediated diseases 
(107). 
 
1.5.3 Thiopeptide resistance 
 
Different mechanisms exist in thiopeptide producing bacteria which ensure resistance to 
the toxic action of self-produced or exogenous compounds. A common self-resistance 
mechanism consists of methylation of the 23S rRNA at the A1067 2´-hydroxyl group 
through action of chromosomally encoded methyltransferases. Methylation at this key 
position prevents the binding of thiopeptide compounds to the ribosome (105). Two 
residues, A1067 and A1095 (E. coli numbering), of the 23S rRNA are crucial for 
thiopeptide recognition and mutations at these positions lead to reduced binding affinity 
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and confer thiopeptide resistance (8). Resistance-conferring mutations in ribosomal 
protein L11 can be caused by single amino acid substitutions (especially at key residue 
P25). Furthermore, mutants deficient in L11 or with truncated versions of L11 lacking 
the N-terminal ligand-binding domain, have been described (8 and references cited 
therein). 
 
Also in EF-Tu-inhibitor producing bacteria, the presence of mutations in the amino acid 
sequence of the target protein can confer resistance. The producer of EF-Tu inhibitor 
GE2270A, Planobispora rosea, has a single tuf gene encoding an EF-Tu protein 
completely resistant to the inhibitory action of GE2270A (77). Streptomyces spp. 
producing EF-Tu targeting antibiotics can have up to three gene variants encoding 
sensitive and resistant forms of otherwise functional EF-Tu proteins which can be 
expressed in a growth-phase dependent manner and at least partly confer self-resistance 
(86). 
 
1.5.4 Thiopeptide engineering 
 
Since the biosynthetic origin of thiopeptides was only elucidated recently, engineering 
and structure-activity relationship studies of thiopeptide antibiotics are still at their very 
beginning. The aim of these studies is mostly to create novel thiopeptide molecules with 
improved solubility while still retaining biological activity. Using semi-synthesis from 
nocathiacin I, Xu et al. were able to obtain nocathiacin acid as a more versatile 
intermediate for chemical creation of more soluble amide analogs (117). Since the 
chemical conversion process was tedious and involved toxic reagents, an in situ 
production of nocathiacin acid was more desirable. Wei et al. were able to achieve in 
situ bioconversion of nocathiacin I in Amycolatopsis fastidiosa LCB1001. By adding 
CuCl2 to fermentation cultures, the activity of enzymes involved in hydrolysis of the 
C-terminal dehydroalanine tail could be modified yielding the desired nocathiacin acid 
(112). 
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Two recent studies describe the generation and determination of antimicrobial activities 
of a range of thiocillin variants (1, 17). The thiocillin biosynthetic gene cluster from 
Bacillus cereus ATCC 14579 contains four tandem genes, tclE-H, each of them 
encoding identical copies of the thiocillin precursor peptide. The observation that 
thiocillin production could be rescued in a non-producing mutant where all four genes 
had been deleted via introduction of a single plasmid-based copy of one precursor 
peptide gene was used as basis for structure-activity studies (1). Precursor peptide 
variants were created using site-directed mutagenesis exchanging in total 14 amino 
acids at five different positions in the original precursor. The introduction of these 
variants into the B. cereus tclE-H mutant gave rise to 65 novel thiocillin variants (1). 
However, while antibiotic activity of conservative variants was maintained, variants 
where additional charges had been introduced were inactive (1). A second round of 
mutations consisted of a complete alanine scan of all 14 residues of the thiocillin 
precursor and a serine scan of the six cysteine residues which are present as thiazoles in 
the matured thiocillins (17). It was shown that substitutions of the two serine residues 
building the pyridine core of thiocillin resulted in complete loss of thiocillin or any 
derivatives. Substitutions affecting heterocycle formation in the thiocillin macrocycle 
resulted in derivatives with dramatically reduced activity. Even the disruption of a 
single thiazole in the thiocillin macrocycle significantly diminished or abolished activity 
of the resulting product indicating the importance of global conformational rigidity of 
the thiopeptide macrocycle for biological activity. Also substitution in regions proposed 
to be involved in binding to ribosomal protein L11 led to drastically reduced activity 
(17). 
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2 AIMS OF THE STUDY 
 
The aim of this study was to analyze marine actinomycete bacteria from the Trondheim 
fjord for their antibiotic production potential. The analyses were to be focused on 
indigenous marine isolates with high potential to produce bioactive secondary 
metabolites.  
 
Many biologically active secondary metabolites, including antibiotics, are synthesized 
by actinomycete bacteria through polyketide synthase (PKS) and non-ribosomal peptide 
synthetase (NRPS) pathways. A PCR screening for PKS and NRPS genes was used as a 
tool to estimate the genetic potential of isolates to produce bioactive compounds.  
 
Since the expression of gene clusters for secondary metabolites is dependent on 
specific, usually unknown environmental triggers, fermentation studies including a wide 
range of cultivation media should be used to identify conditions favorable for synthesis 
of antimicrobial compounds. Isolates with good antibacterial and/or antifungal activity 
would then be chosen based on the results of this screening for further studies.  
 
These studies would involve identification of the active compounds and cloning of the 
corresponding biosynthetic gene clusters, followed by functional analyses and, if 
feasible, biosynthetic engineering.  
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3 SUMMARY OF RESULTS AND DISCUSSION 
3.1 Isolation of actinomycetes from fjord sediments and sponges 
 
Analyses performed in this study were based on two different actinomycete collections 
selected from isolate libraries which were established from three different sampling 
sources in the Trondheim fjord, Norway. In the three independent isolations, 
actinomycetes were recovered from (i) shallow water sediments (4.5-28 m depth), 
(ii) sediments from deeper fjord regions (10-547 m depth) and (iii) from different 
sponge species recovered from 60 and 120 m depth.  
 
Different enrichment techniques in combination with selective agar media supporting 
selection and growth of actinomycete bacteria were applied. Sediment samples were 
generally pre-treated by desiccation, which favored the growth of spore-forming 
bacteria. Other methods were applied to permit growth of only filamentous 
actinomycetes (the filter-technique (91)), or of only certain actinomycete genera, e.g. by 
applying different kinds of sample irradiation (18, 39, 64) or differential centrifugation 
(43). For cultivation, rich media, often with complex carbon sources such as chitin to 
exploit enzymatic capabilities of actinomycetes enabling them to use a variety of 
substrates, as well as nutrient-poor, habitat-specific media (e.g. sediment- and sponge-
extract agar) were used. Cultivation media were generally supplemented with different 
antibiotics including nalidixic acid, to prevent the growth of Gram-negative bacteria, 
and nystatin or cycloheximide to prevent fungal growth.  
 
Using different combinations of these methods, a diverse collection of ca. 10.000 
actinomycete isolates was established. Paper I describes further studies on 35 shallow-
water sediment-derived isolates, while Paper II is based on analysis of 27 deeper 
sediment and sponge-derived actinomycetes. 
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3.2 Influence of seawater on growth of marine-derived isolates 
 
The growth of actinomycete isolates on seawater-containing agar media was compared 
to growth on seawater-deficient media (Papers I and II). It was observed that marine-
derived isolates were differently affected by the presence of seawater in the growth 
medium and growth phenotypes ranged from obligatory dependence on seawater (no 
growth in its absence) to varying degrees of preference for seawater (smaller colony 
size, later onset of sporulation etc. in the absence of seawater) to opposite effects (no 
growth in the presence of seawater). A positive influence of seawater on growth 
indicated that the corresponding isolates could represent indigenous marine bacteria 
which have adapted to the marine environment in the course of evolution (48). For 
Paper II, seawater dependency or preference was used as a criterion to select a 
collection of 27 marine actinomycetes for further studies. 
 
3.3 Assessing biodiversity and antibiotic production potential of 
actinomycete isolates 
 
Molecular taxonomy based on amplification and sequencing of 16S rRNA genes was 
used as a tool to assess the biodiversity of selected sub-collections of actinomycete 
isolates (Papers I and II). 16S rRNA gene sequence analysis provided information about 
similarity to published sequences of other actinomycetes, and the preliminary 
taxonomic information was used to assess diversity and potential novelty of the selected 
isolates. The preliminary identification of genus and species of isolates can be very 
useful as it can aid in dereplication of strain collections and is often crucial for further 
analyses such as fermentation studies and genetics.  
 
A phylogenetic tree based on the 16S rRNA gene sequence data for the isolates 
described in Paper I revealed high biodiversity of actinomycetes in this collection 
containing representatives of 11 different actinomycete genera, two of which (Knoellia 
and Glycomyces) had not been reported among marine-derived isolates by then. Based 
on the topology of the derived phylogenetic tree, it could be assumed that potentially 
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new species for 10 of the 11 genera were represented in the collection. Preliminary 
classification of the 27 isolates in Paper II revealed representatives of eight different 
actinomycete genera with the majority of isolates typed as Nocardiopsis, 
Micromonospora and Streptomyces spp. Many of the isolates showed closest 16S rRNA 
gene sequence similarity to marine-derived actinomycetes. 
 
Apart from the phylogenetic analysis, the potential of isolates in both collections to 
produce secondary metabolites was assessed. A PCR screening for genes associated 
with the biosynthesis of polyketide and peptide-based antibiotics was performed. Three 
sets of degenerate primers were employed to specifically target genes encoding 
ketosynthase (KS) domains of modular type I and iterative type II polyketide synthases 
(PKSs) as well as adenylation domains of non-ribosomal peptide synthetases (NRPSs). 
In both collections, the overall majority of isolates yielded PCR products for at least one 
of the biosynthetic systems, and for 30% (Paper I) up to 55 % (Paper II) of isolates 
amplification products for all three target genes could be obtained. This demonstrated 
the genetic potential of most of the selected isolates for biosynthesis of secondary 
metabolites with polyketide and/or peptide backbone.  
 
Combined with sequence and bioinformatics analyses of the amplified gene fragments, 
this approach can be a powerful tool to predict the nature of encoded compounds and to 
select strains with the highest potential to produce novel secondary metabolites for 
fermentation studies. Furthermore, amplified gene fragments can also be used for 
identification and cloning of the corresponding biosynthetic gene clusters by using them 
as probes in the screening of genomic libraries.  
 
3.4 Screening of 27 marine actinomycetes for production of antibacterial 
and antifungal compounds  
 
Twenty-seven selected isolates displaying a preference for or dependence on seawater 
for growth were analyzed for the production of antibacterial and antifungal compounds 
(Paper II). Fermentations of isolates for secondary metabolite production were 
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performed in 96-well microtitre plates with 800 μl culture volume and using up to 14 
different media. It has been shown that conditions in micro-cultures ( 3 ml) with 
respect to oxygen transfer rates, biomass yield and secondary metabolite production 
compare well or exceed those achieved in larger scale shake-flask cultivations (74, 100). 
Using this cultivation system, all steps in the screening procedure, such as fermentation, 
extraction of fermentation cultures, storage of extracts and bioassays, could be 
performed efficiently in 96-well format. Crude extracts of the entire fermentation 
cultures were prepared with DMSO and analyzed for antibacterial/antifungal activity in 
whole-cell-based growth inhibition assays against Micrococcus luteus and Candida 
albicans. Fifteen out of 27 isolates subjected to this screen produced compounds 
inhibiting the growth of at least one of the indicator strains.  
 
Those extracts displaying the strongest antagonistic activity (nine of 15 active extracts) 
were subsequently analyzed for activity against multi-resistant clinical isolates of 
Enterococcus faecium and C. albicans. Eight out of the nine extracts tested also 
inhibited the growth of the multi-resistant test strains. Extracts of isolate TSF65-07, 
preliminary typed as Nocardiopsis sp. based on analysis of the 16S rRNA gene 
sequence, caused potent growth inhibition of vancomycin-resistant E. faecium while 
displaying no activity against C. albicans. Hence, isolate TFS65-07 was chosen for 
further studies aiming at identification of the active antibacterial compound.  
 
Although the fermentation screening only included few variables in form of different 
media, seawater content and cultivation periods, more than 50% of the subjected 
isolates produced antibacterial/antifungal compounds. It seems likely that through 
further variation of cultivation conditions (e.g. more media/different pH, additives, 
cultivation temperature) conditions for expression of secondary metabolite gene clusters 
in the remaining isolates could be triggered as well (14). 
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3.5 Identification, isolation and structure elucidation of the new 
thiopeptide antibiotic TP-1161 
 
Based on the results from the extract screenings, those conditions that yielded the 
highest bioactivity were chosen for upscaled production of the antibacterial compound 
by TFS65-07 in shake flasks. Culture extracts were subjected to activity-guided 
fractionation and antibacterial fractions analyzed by LC-DAD-TOF. The UV absorption 
spectrum of these fractions revealed a UV absorption maximum at 250 nm, which 
correlated with a significant MS-peak. To obtain sufficient material for further 
characterization, upscaled production in both shake flasks and batch fermentors were 
performed. The antibacterial compound could be purified, and using LC-DAD-TOF 
analysis its accurate mass was determined to be between 1161.2619 and 1161.2665. A 
database search (Dictionary of Natural Products) for molecules with a similar accurate 
mass and UV absorption maximum did not yield any significant hits, suggesting the 
novelty of the identified compound. Thus, it was decided to solve the molecular 
structure of the potentially new antibacterial compound. HRMS and NMR experiments 
provided the molecular formula (C50H47N15O13S3) and determination of the structure 
using NMR, HSQC and HMBC experiments revealed the compound to be a new 
member of the thiopeptide antibiotics (Figure 3.1). The compound was designated 
TP-1161.  
 
 
Figure 3.1. Molecular structure of the thiopeptide antibiotic TP-1161. 
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The TP-1161 structure is like other members of this antibiotic family defined by a 
macrocyclic peptide framework consisting of modified amino acid residues including 
multiple heterocycles and dehydrated amino acids, and a central 6-membered nitrogen-
containing heterocycle (5). Structure and oxidation state of the central heterocyclic 
domain serve as basis for classifying thiopeptides into 5 different series (series a-e). The 
presence of a characteristic 2,3,6-tri-substituted pyridine domain in TP-1161 defined the 
molecule as a series d thiopeptide, the numerically largest series, which includes 
members such as the very first discovered thiopeptide micrococcin and other well-
studied compounds like the thiocillins and GE2270 (5). Most closely related compounds 
in this series include berninamycin A and B, isolated from Streptomyces bernensis, and 
the A10255 complex produced by S. gardnerii NRRL 15537 based on the shared central 
oxazolethiazolepyridine-type d domain (Figure 1.4) (5). 
 
3.6 Isolation of the TP-1161 biosynthetic gene cluster and pathway 
proposition 
 
Early LC/GC and MS results indicated the isolated antibacterial compound to be of 
peptidic nature. Since most peptide antibiotics are known to be produced by NRPS 
systems, initial attempts to isolate the corresponding biosynthetic gene cluster were 
based on an NRPS-based screening approach. A genomic cosmid library of producer 
Nocardiopsis sp. TFS65-07 was constructed and 3072 cosmid clones screened using 
PCR-amplified gene fragments encoding NRPS adenylation domains as probes. 
However, identification of positive cosmid clones followed by partial DNA sequencing 
did not yield any putative gene cluster that could be linked to the preliminary data for 
the antibacterial peptide-based antibiotic from TFS65-07. 
 
The structure determination, proving TP-1161 to be a member of the thiopeptide 
antibiotic family was followed by three almost simultaneously published reports 
elucidating the biosynthetic origin of thiopeptides (55, 68, 123). Overthrowing the by 
then widely accepted theory of NRPS-mediated thiopeptide biosynthesis, the reports 
documented that the highly modified peptides are generated instead by ribosomal 
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synthesis from chromosomally encoded precursor peptide genes and that all 
modifications, including heterocyclisation and dehydration of amino acids, are 
introduced posttranslationally by a range of conserved enzymes, some of them 
reminiscent to enzymes involved in the biosynthesis of other ribosomally encoded 
peptide antibiotics including lantibiotics and cyanobactins (62).  
 
The new data prompted the change of strategy for identification of the TP-1161 gene 
cluster. A draft genome sequence of Nocardiopsis sp. TFS65-07 was obtained covering 
the about 6 MB genome in form of 373 contigs with an average size of 16 kb. Based on 
the information about conserved thiopeptide tailoring reactions, the TP-1161 molecular 
structure could be used to deduce the primary amino acid sequence constituting the 
unmodified TP-1161 structural peptide (Figure 3.2). 
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Figure 3.2. Prediction of TP-1161 precursor peptide sequence based on molecular 
structure of modified thiopeptide framework. 
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The draft genome was then scanned for the gene encoding the structural TP-1161 
peptide. This approach led to identification of the TP-1161 biosynthetic gene cluster 
proposed to consist of 13 open reading frames encoding two thiopeptide precursors and 
11 enzymes mediating posttranslational modifications and host resistance (Figure 3.3). 
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Figure 3.3. Organization of the TP-1161 biosynthetic gene cluster in Nocardiopsis sp. 
TFS65-07. Displayed are the proposed core biosynthetic genes (tpa) with deduced 
functions and surrounding regions. 
 
Annotation of the genomic region using FramePlot and protein BLAST analyses, along 
with data from the literature allowed functional predictions for the genes proposed to 
constitute the TP-1161 biosynthetic pathway and surrounding regions (Table 3.1). 
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Table 3.1. Deduced functions of open reading frames in the TP1161 biosynthetic gene 
cluster and surrounding regions. 
Gene designation  Proteina Proposed function 
orf1 142 50S ribosomal protein L11 
orf2 225 50S ribosomal protein L1 
orf3 175 50S ribosomal protein L10 
orf4 129 50S ribosomal protein L7/L12 
orf5 1155 DNA-directed RNA polymerase subunit  
orf6 1292 DNA-directed RNA polymerase subunit ’ 
orf9 1060 Unknown 
tpaA 48 TP-1161 precursor peptide 
tpaB 355 Unknown 
tpaC 448 Cyclodehydratase 
tpaD 200 Cyclodehydratase 
tpaE 546 Thiazoline/oxazoline dehydrogenase 
tpaF 233 Thiazoline/oxazoline dehydrogenase 
tpaG 391 Unknown 
tpaH 621 Cyclodehydratase/peptidase 
tpaI 269 23S rRNA methyltransferase 
tpaJ 386 Dehydrogenase 
tpaX 48 Precursor peptide for unknown thiopeptide 
tpaK 900 Serine/threonine dehydratase 
tpaL 310 Serine/threonine dehydratase 
orf8 123 Ribosomal protein S12P 
orf9 156 Ribosomal protein S7P 
orf10 703 Translation elongation factor EF-G 
orf11 397 Translation elongation factor EF-Tu 
aprotein size in amino acids 
 
Unusual for thiopeptide biosynthetic gene clusters, the TP-1161 cluster was found to 
encode a second thiopeptide precursor (TpaX) with 70% homology to the TP-1161 
precursor TpaA. However, the posttranslationally modified product of TpaX could not 
be detected in fermentation extracts of TFS65-07.  
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Based on the predicted functions of tpa genes in the cluster, a model for TP-1161 
biosynthesis was proposed (Figure 3.4). In total 10 different enzymes are predicted to 
act on the TP-1161 precursor peptide, introducing posttranslational modifications in 13 
out of 15 residues of the structural peptide and catalyzing macrocyclization and 
elimination of the leader peptide.  
 
The predicted cyclodehydratases TpaC and TpaD in combination with the assigned 
dehydrogenases TpaE and TpaF mediate oxazole and thiazole formation in TP-1161 by 
(i) cyclization of serine, cysteine and threonine side chain onto their preceding carbonyl 
groups and (ii) oxidation of the resulting dehydroheterocycles to aromatic oxazoles and 
thiazoles. The lantibiotic dehydratase homolog TpaL is predicted to be involved in 
dehydration of serine and threonine residues yielding a single dehydrobutyrine as well 
as multiple dehydroalanine moieties in TP-1161.  
 
Formation of the central pyridine domain by macrocyclization and elimination of the 
leader peptide is proposed to be achieved through concerted action of two enzymes, 
cyclodehydratase/peptidase TpaH and a second lantibiotic dehydratase homolog, TpaK. 
Two serine groups and the carboxyl group of an adjacent cysteine residues have been 
established as the origin of the central pyridine domain (76). Cycloaddition of these 
residues is proposed to require dehydration of the two serine residues prior to formation 
of a dehydropiperidine ring intermediate from which the pyridine moiety can be 
obtained after dehydration and elimination of the leader peptide (62 and references cited 
therein). Dehydration of two serine residues (residues 11 and 12 in the structural 
peptide) through action of TpaK dehydratase coupled with cyclodehydration of the 
N-terminal cysteine residue and cyclization could thus yield the pyridine domain in 
TP-1161. Bioinformatics analysis of TpaH revealed a C-terminal peptidase domain in 
addition to the YcaO-family domain commonly present in cyclodehydratases. In 
addition to its cyclodehydratase activity this indicated a possible role of TpaH in 
cleavage of the leader peptide during macrocyclization.  
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Figure 3.4. Proposed pathway for TP-1161 biosynthesis in TFS65-07. Displayed is the 
conversion of the unmodified linear precursor peptide (LP = leader peptide) to the final 
decorated thiopeptide macrocycle through action of the proposed TP-1161 modification 
enzymes (Tpa). 
 
Also unusual for thiopeptides, the terminus of the mature TP-1161 molecule consists of 
an aminoacetone instead of typically present carboxamide or carboxyl groups. This 
posed the question of how the terminus of TP-1161 is generated during biosynthesis. 
The TP-1161 structural peptide contains a C-terminal threonine indicating that the 
aminoacetone group is derived from this amino acid. A suggested candidate for 
performing this tailoring reaction is TpaJ, assigned as iron-dependent dehydrogenase 
with similarity to 4-hydroxybutyrate dehydrogenases. The latter enzyme catalyzes the 
conversion of 4-hydroxybutanoic acid to succinate semialdehyde. High structural 
similarity between 4-hydroxybutanoic acid and threonine led to the hypothesis that 
aminoacetone can be obtained through oxidative action of TpaJ dehydrogenase, 
followed by spontaneous decarboxylation of the intermediate and enol-keto 
tautomerization. 
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3.7 Functional confirmation of the TP-1161 gene cluster  
 
For functional studies of genes involved in TP-1161 biosynthesis in the producer 
TFS65-07, a gene transfer system in form of intergeneric conjugation from E. coli (54) 
was established using derivatives of the mobilizable suicide vector pK18mob (97). To 
verify involvement of the identified genetic locus in TP-1161 biosynthesis, the genes 
encoding the two putative cyclodehydratases, TpaC and TpaH, were inactivated. Two 
mutants were created, one obtained from gene disruption of tpaC and the other one from 
insertional inactivation of tpaH. Both mutants lost the ability to produce TP-1161, 
confirming a role of both enzymes in the biosynthesis of TP-1161. However, as 
described for other thiopeptides, disruptions of cyclodehydratase genes usually do not 
yield any identifiable derivatives, thus preventing any conclusions about functional 
assignments or the order of posttranslational modifications. 
 
To investigate the putative role of TpaJ in tailoring the TP-1161 terminal threonine, an 
in-frame deletion mutant of tpaJ was created. According to the proposed hypothesis, the 
tpaJ mutant should produce a TP-1161 derivative with a terminal threonine and thus 
produce a more soluble derivative due to the presence of the threonine carboxyl 
terminus. Although the successful in-frame deletion of tpaJ was confirmed by PCR and 
Southern blot analyses, neither TP-1161 nor any new derivative could be detected in 
fermentation extracts of the corresponding mutant.  
 
Posttranslational tailoring of thiopeptides introduces structural constraints and provides 
hydrolytic stability to the final product (108). Since the order of tailoring reactions is 
not known, the inactivation of any of the modification enzyme-encoding genes could 
lead to either abolished production or the generation of intermediates or derivatives 
which are unstable and subject to rapid proteolytic degradation preventing detection. 
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3.8 Attempt to heterologously express the TP-1161 gene cluster in 
Streptomyces coelicolor M512 
 
To establish a more versatile platform for systematic functional gene analysis and for 
production of TP-1161 derivatives by biosynthetic engineering, heterologous expression 
of the entire TP-1161 cluster was attempted in S. coelicolor M512. The latter is an 
engineered S. coelicolor strain deficient in production of actinorhodin (Act) and 
undecylprodigiosin (Red) (35), and thus can be used as a convenient host for 
heterologous production and simplified detection of secondary metabolites due to low 
host background (30). For site-specific integration of the gene cluster into the genome 
of M512, the SuperCos1-based cosmid 8-B9 carrying the entire TP-1161 cluster and 
surrounding regions was equipped with transfer and integration functions using -Red-
mediated recombination (27, 30) and introduced into M512 by protoplast 
transformation. Recombinant clones were confirmed by Southern blot analysis and 
tested for TP-1161 production. Fermentation extracts of M512 integration mutants were 
prepared from a range of different media and conditions. However, TP-1161 could not 
be detected in any of the extracts, suggesting a lack of functional expression of the tpa 
cluster in M512.  
 
To investigate if this was the case for all introduced tpa genes the recombinant strains 
were analyzed for growth on medium supplemented with thiostrepton. While the 
parental M512 was sensitive to 25 μg/ml thiostrepton, the recombinant strains displayed 
thiostrepton resistance indicating the presence of an active resistance determinant on the 
introduced cosmid. It is high likely that this determinant is represented by TpaI, a 
23S rRNA methyltransferase which is highly similar (66% identity) to the rRNA 
methyltransferase from S. azureus conferring thiostrepton resistance (105). Therefore, it 
could be concluded that not all genes in the tpa cluster are silent in S. coelicolor. 
 
Assuming that all genes necessary for TP-1161 biosynthesis are present on cosmid 
8-B9, the lack of TP-1161 production in M512 could be due to the absence of specific 
regulatory protein(s) in this host that is (are) needed for successful and coordinated 
expression of the tpa genes.  
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No genes encoding potential regulators were identified in the tpa cluster or its 
surroundings and further studies are necessary to analyze the reasons for the lack of 
TP-1161 production in M512. These could include introduction of 8-B9 into alternative 
hosts such as S. lividans or S. albus followed by analyses of TP-1161 production and 
expression analysis of the tpa genes in the different host backgrounds. 
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4 CONCLUDING REMARKS AND PERSPECTIVES 
 
Modern drug discovery still relies heavily on natural products, especially in the area of 
antimicrobials. Bacterial secondary metabolites represent the most important source for 
new antimicrobial compounds both in their native forms and as templates for synthetic 
modifications or de novo design. Members of the bacterial order Actinomycetales have 
delivered most of the antibiotics in clinical use today, and the focus on marine 
actinomycetes contributed new biodiversity and structurally unique bioactive 
compounds to drug development pipelines. 
 
The work presented in this thesis indicates that Trondheim fjord environmental niches 
represent suitable and promising sources for bioprospecting of marine actinomycete 
bacteria. Isolates belonging to diverse and “rare” actinomycete genera could be isolated 
from sediment- and sponge samples. These included members of genera which had 
previously not been isolated from the marine environment, including potentially new 
species. 
 
The marine actinomycetes from the Trondheim fjord were proven to be a rich source for 
antimicrobials. Genetic studies confirmed the potential of the majority of analyzed 
isolates to produce PKS- and NRPS-derived secondary metabolites. Fermentation 
studies could trigger production of antibacterial and/or antifungal compounds from 
more then 50% of the isolates and nine isolates produced compounds with antagonistic 
activity against multi-resistant bacterial and fungal strains. It is likely that through 
further variation of fermentation conditions the production of antimicrobial compounds 
could have been triggered in all isolates. This in turn means that it might be more 
feasible to restrict fermentation analyses to a few “rare” and promising (from the 
genetic point of view) isolates, and to simultaneously extend the variation of cultivation 
conditions for secondary metabolite production. 
 
A new thiopeptide antibiotic, TP-1161, was isolated as a result of the presented 
fermentation studies. The biosynthetic gene cluster was identified by genome mining, 
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isolated and its involvement in the TP-1161 biosynthesis confirmed by gene inactivation 
studies. Due to their unique mode of action and excellent in vitro properties, i.e. 
antibacterial as well as properties relevant to other medical applications, there has been 
renewed interest in developing thiopeptide antibiotics for clinical use in humans. The 
elucidation of origin and mechanisms involved in thiopeptide biosynthesis has laid the 
foundation for genetic engineering and biosynthesis of thiopeptides with improved 
pharmacological properties.  
 
A first step in engineering a more soluble TP-1161 derivative attempted in this study 
failed, and more functional studies on thiopeptide modification enzymes are necessary. 
Of special interest would be studies establishing the order and interdependency of 
posttranslational modifications during thiopeptide maturation. Although not 
successfully accomplished in S. coelicolor M512, heterologous expression would be the 
method of choice for functional gene analysis and TP-1161 engineering. Further studies 
could involve introduction of the TP-1161 cluster to alternative heterologous hosts and 
expression analysis of all genes involved in the biosynthesis. The results could provide 
the knowledge necessary for successful thiopeptide derivatization by genetic 
manipulation of both structural peptides and enzymes mediating their maturation. 
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